Preferred Label : BR-Ibrutinib Regimen;
NCIt synonyms : Imbruvica/Treanda/Rituxan; Ibrutinib/Bendamustine Plus Rituximab; Ibrutinib-Bendamustine-Rituximab; Ibrutinib/Bendamustine/Rituximab Regimen; Ibrutinib/Bendamustine Rituximab; Ibrutinib/Bendamustine/Rituximab; Bendamustine/Ibrutinib/Rituximab;
NCIt related terms : Bendamustine and Rituximab (BR) and Ibrutinib; Bendamustine and Rituximab-rite (BR) and Ibrutinib; Bendamustine and Rituximab-abbs (BR) and Ibrutinib; Bendamustine and Rituximab-arrx (BR) and Ibrutinib; Bendamustine and Rituximab-rixa (BR) and Ibrutinib; Bendamustine and Rituximab-rixi (BR) and Ibrutinib; Bendamustine and Rituximab-pvvr (BR) and Ibrutinib; Bendamustine and Rituximab-blit (BR) and Ibrutinib;
NCIt definition : A regimen consisting of ibrutinib, bendamustine and rituximab that may be used in
the treatment of certain types of relapsed or refractory chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL).;
NCI Metathesaurus CUI : CL969486;
Codes from synonyms : 12331; 128679; 128051; 127737; 127894; 128522; 128208; 128365;
Origin ID : C160548;
UMLS CUI : C5205350;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
